{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:55:00Z","timestamp":1792018500158,"version":"4.4.0"},"reference-count":132,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004329","name":"Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013223","name":"PTC Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.numecd.2020.11.028","type":"journal-article","created":{"date-parts":[[2020,12,9]],"date-time":"2020-12-09T03:49:48Z","timestamp":1607485788000},"page":"733-744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Nutrition in adult patients with selected lysosomal storage diseases"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7504-6407","authenticated-orcid":false,"given":"Francesca","family":"Carubbi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4660-821X","authenticated-orcid":false,"given":"Antonio","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto B.","family":"Burlina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Francini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renzo","family":"Mignani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Pegoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0075-0592","authenticated-orcid":false,"given":"Linda","family":"Landini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"De Danieli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6432-4245","authenticated-orcid":false,"given":"Stefano","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Strazzullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Landini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Barbato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Carubbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Francini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Strazzullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2020.11.028_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.numecd.2020.11.028_bib2","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrm2745","article-title":"Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function","volume":"10","author":"Saftig","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.numecd.2020.11.028_bib3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev-med-122313-085916","article-title":"Lysosomal storage diseases: from pathophysiology to therapy","volume":"66","author":"Parenti","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.numecd.2020.11.028_bib4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.4161\/auto.19469","article-title":"Autophagy in lysosomal storage disorders","volume":"8","author":"Lieberman","year":"2012","journal-title":"Autophagy"},{"key":"10.1016\/j.numecd.2020.11.028_bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bcmd.2016.10.012","article-title":"Energy balance, glucose and lipid metabolism, cardiovascular risk and liver disease burden in adult patients with type 1 Gaucher disease","volume":"68","author":"Nascimbeni","year":"2018","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/ijns3020006","article-title":"Newborn screening for lysosomal storage diseases: a concise review of the literature on screening methods, therapeutic possibilities and regional programs","volume":"3","author":"Schielen","year":"2017","journal-title":"Int J Neonatal Screen"},{"key":"10.1016\/j.numecd.2020.11.028_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"Jama"},{"key":"10.1016\/j.numecd.2020.11.028_bib8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nrendo.2014.35","article-title":"Lee MS Autophagy-a key player in cellular and body metabolism","volume":"10","author":"Kim","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.numecd.2020.11.028_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin Hematol"},{"key":"10.1016\/j.numecd.2020.11.028_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18020441","article-title":"A Review of Gaucher disease pathophysiology, clinical presentation and treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.numecd.2020.11.028_bib11","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.3748\/wjg.14.3968","article-title":"Gaucher disease: new developments in treatment and etiology","volume":"14","author":"Harmanci","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.numecd.2020.11.028_bib12","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ajh.24801","article-title":"Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase\/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry","volume":"92","author":"Mistry","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.numecd.2020.11.028_bib13","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1002\/ajh.24054","article-title":"The history and accomplishments of the ICGG Gaucher registry","volume":"90","author":"Weinreb","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.numecd.2020.11.028_bib14","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/01.GIM.0000153660.88672.3C","article-title":"Individualization of long-term enzyme replacement therapy for Gaucher disease","volume":"7","author":"Andersson","year":"2005","journal-title":"Genet Med"},{"key":"10.1016\/j.numecd.2020.11.028_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejim.2016.07.011","article-title":"Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe","volume":"37","author":"Belmatoug","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.numecd.2020.11.028_bib16","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s10545-011-9368-7","article-title":"Gastrointestinal disturbances and their management in miglustat-treated patients","volume":"34","author":"Belmatoug","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib17","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1007\/s10545-010-9193-4","article-title":"Dietary modifications in patients receiving miglustat","volume":"33","author":"Champion","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bcmd.2017.01.006","article-title":"A pooled analysis of adverse events in 393 adults with Gaucher disease type 1 from four clinical trials of oral eliglustat: evaluation of frequency, timing, and duration","volume":"68","author":"Peterschmitt","year":"2018","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib19","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1399-0004.1984.tb00799.x","article-title":"Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type I disease","volume":"26","author":"Ginsberg","year":"1984","journal-title":"Clin Genet"},{"key":"10.1016\/j.numecd.2020.11.028_bib20","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0026-0495(88)90102-3","article-title":"Abnormalities in lipoprotein metabolism in Gaucher type 1 disease","volume":"37","author":"Le","year":"1988","journal-title":"Metabolism"},{"key":"10.1016\/j.numecd.2020.11.028_bib21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10545-010-9070-1","article-title":"High incidence of cholesterol gallstone disease in type 1 Gaucher disease: characterizing the biliary phenotype of type 1 Gaucher disease","volume":"33","author":"Taddei","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib22","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10545-010-9271-7","article-title":"Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity","volume":"34","author":"Stein","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.atherosclerosis.2008.08.027","article-title":"Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease","volume":"204","author":"de Fost","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2020.11.028_bib24","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s10545-012-9529-3","article-title":"Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study","volume":"36","author":"Zimmermann","year":"2013","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bcmd.2010.10.008","article-title":"Gaucher disease type I: assessment of basal metabolic rate in patients from southern Brazil","volume":"46","author":"Doneda","year":"2011","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib26","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/0026-0495(89)90165-0","article-title":"Resting energy expenditure in Gaucher's disease type 1: effect of Gaucher's cell burden on energy requirements","volume":"38","author":"Barton","year":"1989","journal-title":"Metabolism"},{"key":"10.1016\/j.numecd.2020.11.028_bib27","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0002-9343(97)00134-4","article-title":"Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease","volume":"103","author":"Hollak","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.numecd.2020.11.028_bib28","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10545-007-0621-z","article-title":"Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience","volume":"30","author":"Sido","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib29","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bcmd.2007.09.002","article-title":"Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy","volume":"40","author":"Langeveld","year":"2008","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib30","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1210\/jc.2007-1702","article-title":"Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance","volume":"93","author":"Langeveld","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.numecd.2020.11.028_bib31","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.metabol.2006.10.014","article-title":"Very low serum adiponectin levels in patients with type 1 Gaucher disease without overt hyperglycemia","volume":"56","author":"Langeveld","year":"2007","journal-title":"Metabolism"},{"key":"10.1016\/j.numecd.2020.11.028_bib32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/1476-511X-9-113","article-title":"Sphingolipids: the nexus between Gaucher disease and insulin resistance","volume":"9","author":"Fuller","year":"2010","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ymgme.2008.10.001","article-title":"A cross-sectional, mono-centric pilot study of insulin resistance in enzyme replacement therapy patients with Gaucher type I without overweight","volume":"96","author":"Ucar","year":"2009","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.numecd.2020.11.028_bib34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jceh.2014.02.005","article-title":"Gaucher disease","volume":"4","author":"Nagral","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.numecd.2020.11.028_bib35","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/jbmr.3734","article-title":"Gaucher disease in bone: from pathophysiology to practice","volume":"34","author":"Hughes","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.numecd.2020.11.028_bib36","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1399-0004.2008.00978.x","article-title":"Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study","volume":"73","author":"Sims","year":"2008","journal-title":"Clin Genet"},{"key":"10.1016\/j.numecd.2020.11.028_bib37","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00256-014-1891-9","article-title":"Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat","volume":"43","author":"Sims","year":"2014","journal-title":"Skeletal Radiol"},{"key":"10.1016\/j.numecd.2020.11.028_bib38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10545-008-0779-z","article-title":"Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring","volume":"31","author":"Cox","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","article-title":"UK clinical guideline for the prevention and treatment of osteoporosis","volume":"12","author":"Compston","year":"2017","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.numecd.2020.11.028_bib40","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2020.11.028_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ajmg.c.31317","article-title":"Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten","volume":"160C","author":"Raben","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"10.1016\/j.numecd.2020.11.028_bib42","first-page":"45","article-title":"Role of autophagy in the pathogenesis of Pompe disease","volume":"26","author":"Raben","year":"2007","journal-title":"Acta Myol"},{"key":"10.1016\/j.numecd.2020.11.028_bib43","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/cdd.2012.52","article-title":"The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII)","volume":"19","author":"Nascimbeni","year":"2012","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.numecd.2020.11.028_bib44","article-title":"The Italian GSDII Group. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years","author":"Angelini","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.numecd.2020.11.028_bib45","first-page":"53","article-title":"Urge incontinence and gastrointestinal symptoms in adult patients with Pompe disease: a cross-sectional survey","volume":"17","author":"Karabul","year":"2014","journal-title":"JIMD Rep"},{"key":"10.1016\/j.numecd.2020.11.028_bib46","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ymgme.2010.06.003","article-title":"Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients","volume":"101","author":"Bernstein","year":"2010","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.numecd.2020.11.028_bib47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jns.2015.04.012","article-title":"Gastrointestinal symptoms in late-onset Pompe disease: early response to enzyme replacement therapy","volume":"353","author":"Pardo","year":"2015","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.numecd.2020.11.028_bib48","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000338776","article-title":"Incontinence in late-onset Pompe disease: an underdiagnosed treatable condition","volume":"68","author":"Remiche","year":"2012","journal-title":"Eur Neurol"},{"key":"10.1016\/j.numecd.2020.11.028_bib49","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10545-011-9404-7","article-title":"Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy","volume":"35","author":"van Gelder","year":"2012","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib50","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nmd.2012.12.003","article-title":"Oropharyngeal dysphagia may occur in late-onset Pompe disease, implicating bulbar muscle involvement","volume":"23","author":"Hobson-Webb","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.numecd.2020.11.028_bib51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/bs.afnr.2016.11.008","article-title":"Nutritional aspects of dysphagia management","volume":"81","author":"Gallegos","year":"2017","journal-title":"Adv Food Nutr Res"},{"key":"10.1016\/j.numecd.2020.11.028_bib52","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1111\/j.1747-0080.2007.00153.x","article-title":"The Speech Pathology Association of Australia Limited. Texture-modified foods and thickened fluids as used for individuals with dysphagia: Australian standardised labels and definitions","volume":"64","author":"Dietitians Association of Australia","year":"2007","journal-title":"Nutr Diet"},{"key":"10.1016\/j.numecd.2020.11.028_bib53","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1475-2891-12-54","article-title":"Thickening agents used for dysphagia management: effect on bioavailability of water, medication and feelings of satiety","volume":"12","author":"Cichero","year":"2013","journal-title":"Nutr J"},{"key":"10.1016\/j.numecd.2020.11.028_bib54","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s00270-016-1344-z","article-title":"CIRSE standards of practice guidelines on gastrostomy","volume":"39","author":"Sutcliffe","year":"2016","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.numecd.2020.11.028_bib55","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.bone.2010.06.021","article-title":"Low bone mass in Pompe disease: muscular strength as a predictor of bone mineral density","volume":"47","author":"Van den Berg","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.numecd.2020.11.028_bib56","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mus.22329","article-title":"Consensus treatment recommendations for late-onset Pompe disease","volume":"45","author":"Cupler","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.numecd.2020.11.028_bib57","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"issue":"13","key":"10.1016\/j.numecd.2020.11.028_bib58","doi-asserted-by":"crossref","first-page":"284","DOI":"10.21037\/atm.2019.07.24","article-title":"Multisystem late onset Pompe disease (LOPD): an update on clinical aspects","volume":"7","author":"Toscano","year":"2019","journal-title":"Ann Transl Med"},{"issue":"Supplement 1","key":"10.1016\/j.numecd.2020.11.028_bib59","doi-asserted-by":"crossref","first-page":"s39","DOI":"10.1007\/PL00014270","article-title":"Dietary treatment in late onset acid maltase deficiency","volume":"156","author":"Bodamer","year":"1997","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.numecd.2020.11.028_bib60","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/mus.20665","article-title":"Modification of the natural history of adult onset acid maltase deficiency by nutrition and exercise therapy","volume":"35","author":"Slonim","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.numecd.2020.11.028_bib61","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1007\/s10545-006-0144-z","article-title":"Dietary treatment in adult onset type II glycogenosis","volume":"29","author":"Ravaglia","year":"2006","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1016\/j.numecd.2020.11.028_bib62","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13023-020-01416-6","article-title":"Exercise training alone or in combination with high-protein diet in patients with late onset Pompe disease: results of a cross over study","volume":"15","author":"Sechi","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib63","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.55.5.710","article-title":"The effects of I alanine supplementation in late onset glycogen storage disease Type II","volume":"55","author":"Bodamer","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.numecd.2020.11.028_bib64","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0887-8994(02)00413-7","article-title":"L-alanine supplementation in late infantile glycogen storage disease type II","volume":"27","author":"Bodamer","year":"2002","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.numecd.2020.11.028_bib65","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ymgme.2018.11.014","article-title":"Recommendations for clinical monitoring of patients with acid sphingomyelinase deficiency (ASMD)","volume":"126","author":"Wasserstein","year":"2019","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.numecd.2020.11.028_bib66","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgme.2016.12.008","article-title":"Types A and B Niemann-Pick disease","volume":"120","author":"Schuchman","year":"2017","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.numecd.2020.11.028_bib67","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/B978-0-444-59565-2.00041-1","article-title":"Niemann-Pick diseases","volume":"113","author":"Vanier","year":"2013","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.numecd.2020.11.028_bib68","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jpeds.2006.06.034","article-title":"Acid sphingomyelinase deficiency: prevalence and characterization of an intermediate phenotype of Niemann-Pick disease","volume":"149","author":"Wasserstein","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.numecd.2020.11.028_bib69","doi-asserted-by":"crossref","first-page":"e672","DOI":"10.1542\/peds.2004-0887","article-title":"The natural history of type B Niemann-Pick disease: results from a 10-year longitudinal study","volume":"114","author":"Wasserstein","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.numecd.2020.11.028_bib70","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.tibs.2005.07.007","article-title":"Guilty until proven innocent: the case of NPC1 and cholesterol","volume":"30","author":"Ioannou","year":"2005","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.numecd.2020.11.028_bib71","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0960-9822(01)00396-7","article-title":"Critical role for glycosphingolipids in Niemann-Pick disease type C","volume":"11","author":"Zervas","year":"2001","journal-title":"Curr Biol"},{"key":"10.1016\/j.numecd.2020.11.028_bib72","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1086\/320599","article-title":"Niemann-Pick C variant detection by altered sphingolipid trafficking and correlation with mutations within a specific domain of NPC1","volume":"68","author":"Wasserstein","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.numecd.2020.11.028_bib73","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1474-4422(07)70194-1","article-title":"Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study","volume":"6","author":"Patterson","year":"2007","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.numecd.2020.11.028_bib74","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1750-1172-5-16","article-title":"Niemann-Pick disease type C","volume":"5","author":"Vanier","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib75","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13023-015-0284-z","article-title":"Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study","volume":"10","author":"Patterson","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib76","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.numecd.2020.11.028_bib77","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib78","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/1756283X16642936","article-title":"Understanding the gastrointestinal manifestations of Fabry disease: promoting prompt diagnosis","volume":"9","author":"Zar-Kessler","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.numecd.2020.11.028_bib79","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.dld.2018.02.011","article-title":"Non-specific gastrointestinal features: could it be Fabry disease?","volume":"50","author":"Hilz","year":"2018","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib80","first-page":"CD006663","article-title":"Enzyme replacement therapy for Anderson-Fabry disease","volume":"7","author":"El Dib","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.numecd.2020.11.028_bib81","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet Med"},{"key":"10.1016\/j.numecd.2020.11.028_bib82","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","article-title":"Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \"kidney disease: improving global outcomes\" (KDIGO) controversies conference","volume":"91","author":"Eng","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.numecd.2020.11.028_bib83","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1093\/ndt\/gfy089","article-title":"Enzyme replacement therapy dose and Fabry nephropathy","volume":"33","author":"Ortiz","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.numecd.2020.11.028_bib84","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","article-title":"Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease","volume":"52","author":"Germain","year":"2015","journal-title":"J Med Genet"},{"key":"10.1016\/j.numecd.2020.11.028_bib85","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/gim.2016.122","article-title":"The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat","volume":"19","author":"Benjamin","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.numecd.2020.11.028_bib86","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J Med Genet"},{"key":"10.1016\/j.numecd.2020.11.028_bib87","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2020.11.028_bib88","doi-asserted-by":"crossref","first-page":"448","DOI":"10.3389\/fphar.2017.00448","article-title":"Pharmaceutical chaperones and proteostasis regulators in the therapy of lysosomal storage disorders: current perspective and future promises","volume":"8","author":"Mohamed","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.numecd.2020.11.028_bib89","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13023-018-0813-7","article-title":"Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial","volume":"13","author":"Schiffmann","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib90","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/bmj.39576.709711.80","article-title":"Nephrotic syndrome in adults","volume":"336","author":"Hull","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.numecd.2020.11.028_bib91","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s10157-014-1031-9","article-title":"Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: general therapy","volume":"19","author":"Kaku","year":"2015","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.numecd.2020.11.028_bib92","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11255-015-1170-2","article-title":"Effect of restricted protein diet supplemented with keto analogues in chronic kidney disease: a systematic review and meta-analysis","volume":"48","author":"Jiang","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.numecd.2020.11.028_bib93","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/j.jrn.2007.02.003","article-title":"Continuous ambulatory peritoneal dialysis patients are unable to increase dietary intake to recommended levels","volume":"17","author":"Sutton","year":"2007","journal-title":"J Ren Nutr"},{"key":"10.1016\/j.numecd.2020.11.028_bib94","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1053\/ajkd.2001.20748","article-title":"National kidney foundation K\/DOQI clinical practice guidelines for nutrition in chronic renal failure","volume":"37","author":"Kopple","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib95","first-page":"CD011998","article-title":"Dietary interventions for adults with chronic kidney disease","volume":"4","author":"Palmer","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.numecd.2020.11.028_bib96","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.numecd.2020.11.028_bib97","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","article-title":"Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy","volume":"5","author":"Hoffmann","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.numecd.2020.11.028_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124987","article-title":"Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial","volume":"10","author":"Wijburg","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.numecd.2020.11.028_bib99","series-title":"Fabry disease: Perspectives from 5 Years of FOS","article-title":"Gastrointestinal manifestations of Fabry disease","volume":"Chapter 28","author":"Keshav","year":"2006"},{"key":"10.1016\/j.numecd.2020.11.028_bib100","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.3748\/wjg.v23.i21.3771","article-title":"Diet in irritable bowel syndrome: what to recommend, not what to forbid to patients!","volume":"23","author":"Cozma-Petrut","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.numecd.2020.11.028_bib101","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2013.386","article-title":"Differential Effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI","volume":"109","author":"Murray","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.numecd.2020.11.028_bib102","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1136\/gutjnl-2017-313750","article-title":"The low FODMAP diet: recent advances in understanding its mechanisms and efficacy in IBS","volume":"66","author":"Staudacher","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.numecd.2020.11.028_bib103","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","article-title":"Overview of the mucopolysaccharidoses","volume":"50","author":"Muenzer","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.numecd.2020.11.028_bib104","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1017\/S1462399408000550","article-title":"The mucopolysaccharidoses: a success of molecular medicine","volume":"10","author":"Clarke","year":"2008","journal-title":"Expet Rev Mol Med"},{"key":"10.1016\/j.numecd.2020.11.028_bib105","doi-asserted-by":"crossref","first-page":"v49","DOI":"10.1093\/rheumatology\/ker396","article-title":"Therapy for the mucopolysaccharidoses","volume":"50","author":"Valayannopoulos","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.numecd.2020.11.028_bib106","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s41110-018-0066-1","article-title":"Evaluation of food intake in patients with mucopolysaccharidosis","volume":"43","author":"Monteiro","year":"2018","journal-title":"Nutrire"},{"key":"10.1016\/j.numecd.2020.11.028_bib107","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10545-012-9500-3","article-title":"Management of mucopolysaccharidosis type IH (Hurler's syndrome) presenting in infancy with severe dilated cardiomyopathy: a single institution's experience","volume":"36","author":"Wiseman","year":"2013","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib108","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","article-title":"Mucopolysaccharidosis I: management and treatment guidelines","volume":"123","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.numecd.2020.11.028_bib109","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ymgme.2007.01.011","article-title":"The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I","volume":"91","author":"Pastores","year":"2007","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.numecd.2020.11.028_bib110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.bmt.1703839","article-title":"Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines","volume":"31","author":"Peters","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.numecd.2020.11.028_bib111","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.24246","article-title":"Early treatment is associated with improved cognition in Hurler syndrome","volume":"76","author":"Poe","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.numecd.2020.11.028_bib112","doi-asserted-by":"crossref","first-page":"29684","DOI":"10.1074\/jbc.M109.020818","article-title":"Metabolic adaptations to interrupted glycosaminoglycan recycling","volume":"284","author":"Woloszynek","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.numecd.2020.11.028_bib113","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.expneurol.2015.12.012","article-title":"Selective normalisation of regional brain bis(monoacylglycero)phosphate in the mucopolysaccharidosis 1 (Hurler) mouse","volume":"277","author":"Saville","year":"2016","journal-title":"Exp Neurol"},{"key":"10.1016\/j.numecd.2020.11.028_bib114","first-page":"77","article-title":"Adverse effects of genistein in a mucopolysaccharidosis type I mouse model","volume":"23","author":"Kingma","year":"2015","journal-title":"JIMD Rep"},{"issue":"1\u20132","key":"10.1016\/j.numecd.2020.11.028_bib115","first-page":"171","article-title":"(2004) Metabolism and function of coenzyme Q","volume":"1660","author":"Turunen","year":"2003","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.numecd.2020.11.028_bib116","first-page":"1","article-title":"Coenzyme Q10 and Pyridoxal phosphate deficiency is a common feature in mucopolysaccharidosis type III","volume":"25","author":"Yubero","year":"2016","journal-title":"JIMD Rep"},{"key":"10.1016\/j.numecd.2020.11.028_bib117","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s10545-013-9668-1","article-title":"Treatment effect of coenzyme Q(10) and an antioxidant cocktail in fibroblasts of patients with Sanfilippo disease","volume":"37","author":"Matalonga","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib118","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s00774-016-0762-y","article-title":"Bone mineral density in patients with mucopolysaccharidosis type III","volume":"35","author":"Nur","year":"2017","journal-title":"J Bone Miner Metabol"},{"key":"10.1016\/j.numecd.2020.11.028_bib119","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s11011-017-0009-1","article-title":"Serum global metabolomics profiling reveals profound metabolic impairments in patients with MPS IIIA and MPS IIIB","volume":"32","author":"Fu","year":"2017","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.numecd.2020.11.028_bib120","unstructured":"National Institute of Health. Mucopolysaccharidoses fact sheet. Available online: https:\/\/www.ninds.nih.gov\/Disorders\/Patient-Caregiver-Education\/Fact-Sheets\/Mucopolysaccharidoses-Fact-Sheet (accessed on 23 January 2020)."},{"key":"10.1016\/j.numecd.2020.11.028_bib121","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000334879","article-title":"The evaluation of body composition: a useful tool for clinical practice","volume":"60","author":"Thibault","year":"2012","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.numecd.2020.11.028_bib122","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jada.2005.02.005","article-title":"Comparison of predictive equations for resting metabolic rate in healthy nonobese and obese adults: a systematic review","volume":"105","author":"Frankenfield","year":"2005","journal-title":"J Am Diet Assoc"},{"key":"10.1016\/j.numecd.2020.11.028_bib123","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/000313481708301123","article-title":"Hypoalbuminemia and clinical outcomes: what is the mechanism behind the relationship?","volume":"83","author":"Kim","year":"2017","journal-title":"Am Surg"},{"key":"10.1016\/j.numecd.2020.11.028_bib124","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/acel.12409","article-title":"Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages","volume":"15","author":"Aflaki","year":"2016","journal-title":"Aging Cell"},{"key":"10.1016\/j.numecd.2020.11.028_bib125","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1007\/s00018-012-0962-0","article-title":"Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases","volume":"69","author":"Salminen","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.numecd.2020.11.028_bib126","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.arr.2018.08.004","article-title":"The effect of fasting or calorie restriction on autophagy induction: a review of the literature","volume":"47","author":"Bagherniya","year":"2018","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.numecd.2020.11.028_bib127","doi-asserted-by":"crossref","first-page":"66444","DOI":"10.18632\/oncotarget.12119","article-title":"beta-Hydroxybutyrate suppresses inflammasome formation by ameliorating endoplasmic reticulum stress via AMPK activation","volume":"7","author":"Bae","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.numecd.2020.11.028_bib128","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/15548627.2016.1151597","article-title":"Emerging role of mammalian autophagy in ketogenesis to overcome starvation","volume":"12","author":"Takagi","year":"2016","journal-title":"Autophagy"},{"key":"10.1016\/j.numecd.2020.11.028_bib129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fnins.2019.00005","article-title":"Ketogenic diet and epilepsy: what we know so far","volume":"13","author":"D'Andrea Meira","year":"2019","journal-title":"Front Neurosci"},{"key":"10.1016\/j.numecd.2020.11.028_bib130","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1177\/0271678X15610584","article-title":"Ketogenic diet decreases oxidative stress and improves mitochondrial respiratory complex activity","volume":"36","author":"Greco","year":"2016","journal-title":"J Cerebr Blood Flow Metabol"},{"key":"10.1016\/j.numecd.2020.11.028_bib131","doi-asserted-by":"crossref","first-page":"353","DOI":"10.15252\/emmm.201606547","article-title":"Modulation of mTOR signaling as a strategy for the treatment of Pompe disease","volume":"9","author":"Lim","year":"2017","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.numecd.2020.11.028_bib132","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.tcb.2014.03.003","article-title":"Regulation of mTORC1 by amino acids","volume":"24","author":"Bar-Peled","year":"2014","journal-title":"Trends Cell Biol"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475320305056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475320305056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:16:09Z","timestamp":1760544969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475320305056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":132,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0939475320305056"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2020.11.028","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nutrition in adult patients with selected lysosomal storage diseases","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2020.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}